321 related articles for article (PubMed ID: 20413364)
21. Comparison of the efficacy of atorvastatin and micronized fenofibrate in the treatment of mixed hyperlipidemia.
Bairaktari ET; Tzallas CS; Tsimihodimos VK; Liberopoulos EN; Miltiadous GA; Elisaf MS
J Cardiovasc Risk; 1999 Apr; 6(2):113-6. PubMed ID: 10353071
[TBL] [Abstract][Full Text] [Related]
22. Effect of specific lipoprotein(a) apheresis on coronary atherosclerosis regression assessed by quantitative coronary angiography.
Safarova MS; Ezhov MV; Afanasieva OI; Matchin YG; Atanesyan RV; Adamova IY; Utkina EA; Konovalov GA; Pokrovsky SN
Atheroscler Suppl; 2013 Jan; 14(1):93-9. PubMed ID: 23357149
[TBL] [Abstract][Full Text] [Related]
23. Influence of atorvastatin on coronary calcifications and myocardial perfusion defects in systemic lupus erythematosus patients: a prospective, randomized, double-masked, placebo-controlled study.
Plazak W; Gryga K; Dziedzic H; Tomkiewicz-Pajak L; Konieczynska M; Podolec P; Musial J
Arthritis Res Ther; 2011 Jul; 13(4):R117. PubMed ID: 21774822
[TBL] [Abstract][Full Text] [Related]
24. Atorvastatin and fenofibrate have comparable effects on VLDL-apolipoprotein C-III kinetics in men with the metabolic syndrome.
Chan DC; Watts GF; Ooi EM; Ji J; Johnson AG; Barrett PH
Arterioscler Thromb Vasc Biol; 2008 Oct; 28(10):1831-7. PubMed ID: 18566295
[TBL] [Abstract][Full Text] [Related]
25. Effect of torcetrapib on the progression of coronary atherosclerosis.
Nissen SE; Tardif JC; Nicholls SJ; Revkin JH; Shear CL; Duggan WT; Ruzyllo W; Bachinsky WB; Lasala GP; Tuzcu EM;
N Engl J Med; 2007 Mar; 356(13):1304-16. PubMed ID: 17387129
[TBL] [Abstract][Full Text] [Related]
26. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study.
Mohler ER; Ballantyne CM; Davidson MH; Hanefeld M; Ruilope LM; Johnson JL; Zalewski A;
J Am Coll Cardiol; 2008 Apr; 51(17):1632-41. PubMed ID: 18436114
[TBL] [Abstract][Full Text] [Related]
27. Determinants of arterial wall remodeling during lipid-lowering therapy: serial intravascular ultrasound observations from the Reversal of Atherosclerosis with Aggressive Lipid Lowering Therapy (REVERSAL) trial.
Schoenhagen P; Tuzcu EM; Apperson-Hansen C; Wang C; Wolski K; Lin S; Sipahi I; Nicholls SJ; Magyar WA; Loyd A; Churchill T; Crowe T; Nissen SE
Circulation; 2006 Jun; 113(24):2826-34. PubMed ID: 16769916
[TBL] [Abstract][Full Text] [Related]
28. Regression and shift in composition of coronary atherosclerotic plaques by pioglitazone: insight from an intravascular ultrasound analysis.
Clementi F; Di Luozzo M; Mango R; Luciani G; Trivisonno A; Pizzuto F; Martuscelli E; Mehta JL; Romeo F
J Cardiovasc Med (Hagerstown); 2009 Mar; 10(3):231-7. PubMed ID: 19262209
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of combination of extended release niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol.
Harikrishnan S; Rajeev E; Tharakan JA; Titus T; Ajit Kumar VK; Sivasankaran S; Krishnamoorthy KM; Nair K
Indian Heart J; 2008; 60(3):215-22. PubMed ID: 19240310
[TBL] [Abstract][Full Text] [Related]
30. Combination therapy of candesartan with statin inhibits progression of atherosclerosis more than statin alone in patients with coronary artery disease.
Suzuki T; Nozawa T; Fujii N; Sobajima M; Ohori T; Shida T; Matsuki A; Kameyama T; Inoue H
Coron Artery Dis; 2011 Aug; 22(5):352-8. PubMed ID: 21494127
[TBL] [Abstract][Full Text] [Related]
31. Effects of lipid-lowering therapy on coronary artery remodeling.
Schartl M; Bocksch W; Fateh-Moghadam S
Coron Artery Dis; 2004 Feb; 15(1):45-51. PubMed ID: 15201620
[TBL] [Abstract][Full Text] [Related]
32. Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH Study.
Okazaki S; Yokoyama T; Miyauchi K; Shimada K; Kurata T; Sato H; Daida H
Circulation; 2004 Aug; 110(9):1061-8. PubMed ID: 15326073
[TBL] [Abstract][Full Text] [Related]
33. Cascade plasma filtration during the first year after CABG in patients with hyperlipidemia refractory to statins.
Ezhov MV; Il'ina LN; Safarova MS; Afanasieva OI; Adamova IY; Atanesyan RV; Konovalov GA; Akchurin RS; Pokrovsky SN
Atheroscler Suppl; 2013 Jan; 14(1):101-5. PubMed ID: 23357150
[TBL] [Abstract][Full Text] [Related]
34. Atorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis: a secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
Sillesen H; Amarenco P; Hennerici MG; Callahan A; Goldstein LB; Zivin J; Messig M; Welch KM;
Stroke; 2008 Dec; 39(12):3297-302. PubMed ID: 18845807
[TBL] [Abstract][Full Text] [Related]
35. One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response.
Ferdinand KC; Davidson MH; Kelly MT; Setze CM
Am J Cardiovasc Drugs; 2012 Apr; 12(2):117-25. PubMed ID: 22263674
[TBL] [Abstract][Full Text] [Related]
36. Effects of statins (atorvastatin) on serum lipoprotein levels in patients with primary hyperlipidemia and coronary heart disease.
Jurukovska-Nospal M; Arsova V; Levchanska J; Sidovska-Ivanovska B
Prilozi; 2007 Dec; 28(2):137-48. PubMed ID: 18356785
[TBL] [Abstract][Full Text] [Related]
37. Impact of combined lipid lowering with blood pressure control on coronary plaque regression: rationale and design of MILLION study.
Kawashiri MA; Sakata K; Gamou T; Kanaya H; Miwa K; Ueda K; Higashikata T; Mizuno S; Michishita I; Namura M; Nitta Y; Katsuda S; Okeie K; Hirase H; Tada H; Uchiyama K; Konno T; Hayashi K; Ino H; Nagase K; Terashima M; Yamagishi M
Heart Vessels; 2015 Sep; 30(5):580-6. PubMed ID: 24895097
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia.
Bakker-Arkema RG; Davidson MH; Goldstein RJ; Davignon J; Isaacsohn JL; Weiss SR; Keilson LM; Brown WV; Miller VT; Shurzinske LJ; Black DM
JAMA; 1996 Jan; 275(2):128-33. PubMed ID: 8531308
[TBL] [Abstract][Full Text] [Related]
39. Effect of Vascepa (icosapent ethyl) on progression of coronary atherosclerosis in patients with elevated triglycerides (200-499 mg/dL) on statin therapy: Rationale and design of the EVAPORATE study.
Budoff M; Brent Muhlestein J; Le VT; May HT; Roy S; Nelson JR
Clin Cardiol; 2018 Jan; 41(1):13-19. PubMed ID: 29365351
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of alternate day therapy with atorvastatin and fenofibrate combination in mixed dyslipidemia: a randomized controlled trial.
Harivenkatesh N; David DC; Haribalaji N; Sudhakar MK
J Cardiovasc Pharmacol Ther; 2014 May; 19(3):296-303. PubMed ID: 24516261
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
